Gottlieb suggests sea change as administration looks to alter course of Rx drug prices (BioWorld)
Thursday May 3rd, 2018
Putting drug prices front and center at the Food and Drug Law Institute's (FDLI) annual conference Thursday, FDA Commissioner Scott Gottlieb took on some of the current rules and restrictions that prevent true market-based pricing and competition.
As Gottlieb was speaking at FDLI, the government watchdog group Public Citizen and the Baltimore City Health Department were calling on the Trump administration to address the high price of specific drugs used to reverse life-threatening opioid overdoses. The groups urged the government to use its march-in rights to enable generic competition for Kaleo Inc.'s naloxone auto-injector Evzio and Adapt Pharma Ltd.'s naloxone nasal spray Narcan.